A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders

Flore Zufferey, Elliott H. Sherr, Noam D. Beckmann, Ellen Hanson, Anne Maillard, Loyse Hippolyte, Aurélien Macé, Carina Ferrari, Zoltán Kutalik, Joris Andrieux, Elizabeth Aylward, Mandy Barker, Raphael Bernier, Sonia Bouquillon, Philippe Conus, Bruno Delobel, W. Andrew Faucett, Robin P. Goin‐Kochel, P. Ellen Grant, Louise Harewood, Jill V. Hunter, Sébastien Lebon, David H. Ledbetter, Alastair J. Martin, Katrin Männik, Danielle Martinet, Pratik Mukherjee, Melissa B. Ramocki, Sarah Spence, Kyle J. Steinman, Jennifer Tjernagel, John E. Spiro, Alexandre Reymond, J. Beckmann, Wendy K. Chung, Sébastien JacquemontJournal of Medical Genetics 2012 · DOI

Abstract

The 16p11.2 deletion impacts in a quantitative and independent manner FSIQ, behaviour and body mass index, possibly through direct influences on neural circuitry. Although non-specific, these features are clinically significant and reproducible. Lastly, this study demonstrates the necessity of studying large patient cohorts ascertained through multiple methods to characterise the clinical consequences of rare variants involved in common diseases.

Introduction

This landmark study characterizes the 16p11.2 deletion—a 600 kb genomic loss—as a major driver of both neurodevelopmental disorders and metabolic dysfunction. Identifying a "risk gene" is only the first step; the real challenge lies in deep phenotyping to understand the full range of physical and mental effects. While the 16p11.2 deletion was previously associated with Autism Spectrum Disorder (ASD) and obesity, earlier studies often suffered from ascertainment bias. This research defines the "natural history" of the deletion by examining a massive, diverse cohort of 285 carriers, including relatives who carry the deletion but were never formally diagnosed.

Genomic Context and Methods

The study pooled data from the 16p11.2 European Consortium and the Simons Variation in Individuals Project (Simons VIP). Deletions were confirmed using high-density chromosomal microarrays (aCGH).

Chromosomal location of the 16p11.2 region and various deletion sizes, highlighting the 0.6 Mb BP4-BP5 deletion.

Clinical evaluations included standardized IQ tests (WISC/WAIS), psychiatric interviews (ADI-R/ADOS), and longitudinal growth measurements. The team used Z-scores to normalize body mass index (BMI) and head circumference (HC) across different ages and genders, allowing them to track growth trajectories over time.

Key Insights

  • The "30-Point Drop": The deletion acts as a quantitative "tax" on intelligence. On average, carriers have a Full Scale IQ (FSIQ) about 32 points (2 standard deviations) lower than their non-carrier relatives.
  • Independence of Traits: Crucially, the drop in IQ and the increase in BMI are independent effects of the deletion on different neural circuits (cognitive vs. metabolic).
  • Neurodevelopmental Instability: While only 15% met full ASD criteria, over 80% had some psychiatric or language disorder, suggesting a broad neurodevelopmental impact rather than a single specific disease.
  • Early Brain Overgrowth: Carriers show rapid head circumference increase in infancy (+1.74 Z-score), mirroring growth patterns seen in idiopathic autism.

Clinical Results

  • Cognition: Mean FSIQ for carriers was 74, compared to ~108 in non-carrier relatives. Verbal IQ was typically lower than non-verbal IQ.
  • Metabolism: Obesity is highly penetrant, with a 43-fold increased risk for morbid obesity. By age 7, 50% of carriers are obese, rising to 75% in adulthood.
  • Neurology & Speech: Seizures were present in 24% of carriers. A staggering 83% required speech therapy during childhood, and gross motor delays were common.

Limitations and Future Directions

The 600 kb region contains 29 genes. While the study identifies the region as the culprit, pinpointing specific genes for specific symptoms remains a challenge.

Detailed gene map of the 600 kb BP4-BP5 deletion region, identifying candidate genes like KCTD13 and PRRT2.

Candidate genes include KCTD13 for head size and PRRT2 for seizures. Furthermore, the lack of durable weight loss in this population highlights an urgent need for pharmacological interventions targeting the specific metabolic pathways disrupted by the 16p11.2 deletion.

Summary updated

Abstract

The 16p11.2 deletion impacts in a quantitative and independent manner FSIQ, behaviour and body mass index, possibly through direct influences on neural circuitry. Although non-specific, these features are clinically significant and reproducible. Lastly, this study demonstrates the necessity of studying large patient cohorts ascertained through multiple methods to characterise the clinical consequences of rare variants involved in common diseases.
BibTeX
@article{zufferey2012kb,
  author = {Flore Zufferey and Elliott H. Sherr and Noam D. Beckmann and Ellen Hanson and Anne Maillard and Loyse Hippolyte and Aurélien Macé and Carina Ferrari and Zoltán Kutalik and Joris Andrieux and Elizabeth Aylward and Mandy Barker and Raphael Bernier and Sonia Bouquillon and Philippe Conus and Bruno Delobel and W. Andrew Faucett and Robin P. Goin‐Kochel and P. Ellen Grant and Louise Harewood and Jill V. Hunter and Sébastien Lebon and David H. Ledbetter and Alastair J. Martin and Katrin Männik and Danielle Martinet and Pratik Mukherjee and Melissa B. Ramocki and Sarah Spence and Kyle J. Steinman and Jennifer Tjernagel and John E. Spiro and Alexandre Reymond and J. Beckmann and Wendy K. Chung and Sébastien Jacquemont},
  title = {{A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders}},
  journal = {Journal of Medical Genetics},
  year = {2012},
  doi = {10.1136/jmedgenet-2012-101203},
}
Figure